Search clinical trials for: Brisdelle (paroxetine mesylate)

Total 1908 results

InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Xidian University

Unknown

Investigation of the Changes of Brain Structure and Function in Premature Ejaculation Patients and the Effects of Dapoxetine on Central Neural Activity in Premature Ejaculation Patients

Premature Ejaculation

China
University of Southern Denmark

Unknown

Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study

Depression | Pain
Integrative Skin Science and Research
Actera

Not yet recruiting

The Effects of Cetyl Tranexamate Mesylate on the Appearance of Acne-Related Hyperpigmentation

Hyperpigmentation | Acne | Post-inflammatory Hyperpigmentation
Ball State University

Completed

Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Aging | Endothelial Dysfunction | Arterial Stiffness | Cardiovascular Function

United States
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
UConn Health
National Institute on Aging (NIA); University of Connecticut

Not yet recruiting

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults (Mito-Frail)

Frailty | Aging | Mild Cognitive Impairment

United States
Eisai Inc.

Completed

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Breast Cancer

United States
Sagent Pharmaceuticals Inc.

Completed

Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT)

COVID-19

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body

Chronic Myeloid Leukemia

China
GlaxoSmithKline

Completed

A Local Register Study For Major Depression Of Paroxetine Controlled Release

Depressive Disorder, Major | Major Depressive Disorder (MDD)

China
Esanex Inc.
National Cancer Institute (NCI)

Completed

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Lymphoma | Leukemia | Solid Tumor Malignancy | Lymphoid Malignancy (Lymphoma and CLL)

United States
University of Göttingen
GlaxoSmithKline

Completed

Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic Disorder (Exparox)

Panic Disorder

Germany
GlaxoSmithKline

Completed

Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants

Anxiety Disorders

Mexico
GlaxoSmithKline

Completed

Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects

Depressive Disorder

Japan
Yale University

Completed

Camostat Mesylate in COVID-19 Outpatients

COVID-19

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Eisai Co., Ltd.

Completed

Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)

Inoperable or Recurrent Breast Cancer

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Nystagmus, Acquired | Nystagmus, Congenital Idiopathic

United Kingdom
GlaxoSmithKline

Completed

Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects

Anxiety Disorders

China
Oizumi Hospital

Unknown

Benefits of Switching Antidepressants Following Early Nonresponse

Depression

Japan
Second Affiliated Hospital of Soochow University

Active, not recruiting

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Salivation in Parkinson's Disease

China
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Dong-A Pharmaceutical Co., Ltd.
Dong-A ST Co., Ltd.

Unknown

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine

Healthy Male Subjects

Korea, Republic of
Wuhan Union Hospital, China
Yichang Humanwell Pharmaceutical Co., Ltd., China

Recruiting

PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

Mechanically Ventilated Patients

China
Institut Bergonié
Novartis

Terminated

Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response (MIM)

Leukemia, Myeloid, Chronic-Phase

France
University of Oklahoma

Terminated

Study of Eribulin in Children With Cancer to Determine Safety (ERIBULIN)

Lymphoma | Solid Tumors | Pediatric Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

Head and Neck Cancer

United States, Canada
Novartis

Completed

STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

Sarcoma | Childhood Malignant Fibrous Histiocytoma of Bone

United States
European Organisation for Research and Treatment...

Completed

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

Sarcoma | Small Intestine Cancer | Ovarian Cancer | Endometrial Cancer | Gastrointestinal Stromal Tumor

France, Denmark, Netherlands, Belgium, United Kingdom
Novartis Pharmaceuticals

Completed

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate (Radix)

Progressive Gastrointestinal Stromal Tumor

Germany
Stanford University

Completed

Imatinib in Systemic Sclerosis

Scleroderma, Systemic

United States
Novartis Pharmaceuticals

Completed

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Life Threatening Diseases
UNICANCER

Completed

Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis

Desmoid Tumor

France
University Hospital, Bordeaux
Novartis; Ministry of Health, France

Completed

Efficacy and Safety of Imatinib in Scleroderma (SCLEROGLIVEC)

Scleroderma, Systemic | Scleroderma, Localized

France
Maisonneuve-Rosemont Hospital
Hippocrate Research & Development

Unknown

Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumors

Canada
European Organisation for Research and Treatment...
UNICANCER; Grupo Espanol de Investigacion en Sarcomas; Italian Sarcoma Group

Completed

Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor

Gastrointestinal Stromal Tumor

France, Australia, United Kingdom, Germany, Denmark, Spain
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or Meningioma

Brain and Central Nervous System Tumors

United States
Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Leukemia

United States
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

Sarcoma

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Safety of CB-5339 in Patients With Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
Asan Medical Center

Completed

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

Sarcoma | Gastrointestinal Stromal Tumors

Korea, Republic of
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Sarcoma

United States

3

Subscribe